Immunogenicity for Biotherapeutics will take place March 18-20, 2013 in Baltimore, Maryland. For more information on this session and the rest of the agenda, download the brochure. If you'd like to join us, as a reader of this blog when you register to join us and mention code XP1838BLOG, you'll save 15% off the standard rate!
Featured Session: Highly Sensitive Non-Wash Immunoassays for Immunogenicity and PD/PK Studies
Featured Speaker: Roger Bosse, Global Product Leader, Alpha Technology, PERKIN ELMER
About the session: Biotherapeutics often elicit immune responses and clinical consequences of anti-drug antibodies (ADA) can result in adverse events. The presence of ADA is a safety concern and must be evaluated and correlated with pharmacological or toxicological observations. The development of rapid, sensitive assays for ADA detection is essential. AlphaLISAÒ assays used to detect ADA in serum samples can detect ADA in the low ng/mL range, maintain excellent performance in serum and exhibit high drug tolerance.
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment